A liquid biopsy allows healthcare providers to collect and examine tumor-released biomarkers without the need for surgical interventions and other high-risk procedures. Just by taking a blood sample from the patient and analyzing it, oncologists can detect and monitor certain cancer cells.
What Is a Liquid Biopsy? An Overview
A liquid biopsy is a laboratory test that detects genetic material and other tumor-related substances in a patient’s blood. In comparison to traditional tissue biopsies, this method does not involve surgical excision. Instead, it analyzes biological components that tumors shed into the bloodstream.
Key analytes in liquid biopsy tests include:
- Circulating tumor DNA (ctDNA) are fragments of DNA that originate from cancer cells and enter the bloodstream as tumors grow or die.
- Circulating tumor cells (CTCs) are intact cancer cells that have broken free from a primary tumor and travel through the blood.
- Exosomes and microRNAs are small particles and genetic regulators that contain information about tumor behavior and treatment response.
A liquid biopsy may include one or more of these biomarkers, depending on the clinical purpose and the type of cancer. Physicians can order them to assist in diagnosis, assess treatment response, or monitor disease activity.
What Is the Difference Between a Liquid Biopsy and Traditional Biopsy?
A physician performs a traditional tissue biopsy in a surgical setting. It requires anesthesia and imaging to collect samples. In contrast, a liquid biopsy involves drawing blood during a standard laboratory visit, without anesthesia or surgical preparation. This approach eliminates procedural risks and allows repeated sampling at multiple points during treatment and follow-up.
Moreover, tissue biopsies provide a static snapshot of tumor biology from a single location. Tumors, however, may show genetic variability across different sites or evolve during treatment. Liquid biopsies analyze tumor-derived material from the bloodstream, which may capture a broader range of genetic alterations across metastatic sites. Although liquid biopsy cannot fully replace tissue-based testing in all cases, it is a complementary method with its own benefits.
Advantages of Liquid Biopsies
Liquid biopsies have several benefits across clinical oncology applications. Their utility depends on cancer type, stage, treatment plan, and individual patient characteristics. Benefits include:
- Minimal procedural risk: No incisions or sedation necessary.
- Rapid collection and repeatability: Blood samples can be collected during routine clinical visits and at multiple time points.
- Detection of tumor heterogeneity: Circulating biomarkers may originate from different tumor sites and show evolving mutations.
- Early detection potential: Changes in ctDNA levels may appear before symptoms or imaging findings.
- Monitoring treatment response: Serial measurements of ctDNA may help evaluate the effectiveness of targeted therapies, immunotherapies, or chemotherapy.
- Patient safety and convenience: Frequent blood draws reduce the need for repetitive imaging or surgical interventions.
When the clinical setting allows, physicians use liquid biopsy to identify the cancer type, choose a treatment approach, or track changes in the disease. However, not every patient or tumor type may benefit from this method, which means physicians must determine its usefulness based on the patient’s diagnosis and treatment goals.
Clinical Applications in Current Practice
The U.S. Food and Drug Administration approved the clinical use of two types of liquid biopsies (Guardant360 CDx and FoundationOne Liquid CDx), especially in cancers that release detectable tumor DNA or cells into the bloodstream. Examples of applicable scenarios include:
- Early-stage cancer detection: In high-risk populations, such as people with a family history of cancer or known genetic predispositions, liquid biopsies may assist in detecting malignancy before conventional methods.
- Molecular profiling: Genomic alterations identified through ctDNA analysis can inform targeted therapy selection in cancers such as non-small cell lung cancer.
- Monitoring during treatment: Physicians can track ctDNA to assess how well a tumor responds to therapy. A decrease in ctDNA may suggest reduced tumor burden, whereas an increase may signal resistance.
- Detection of minimal residual disease (MRD): Following curative-intent therapy, low levels of ctDNA may indicate persistent cancer cells before recurrence becomes visible on imaging.
- Recurrence surveillance: Liquid biopsy may detect molecular relapse months before clinical symptoms or radiologic findings appear.
Oncologists may order liquid biopsy tests when they cannot collect tissue or when available samples contain too little material for analysis.
Limitations and Ongoing Challenges
Although liquid biopsies improve cancer monitoring in many cases, the method still has limits that clinical researchers continue to investigate. These include:
- Sensitivity in early-stage cancers: Early tumors may release minimal ctDNA or CTCs, which can reduce detection accuracy.
- False positives from benign conditions: Some genetic alterations may occur in nonmalignant settings, complicating interpretation.
- Lack of standardization: Different laboratories may use varying methods for ctDNA extraction, sequencing, and reporting.
- Limited use across cancer types: Some malignancies release few circulating biomarkers, limiting test reliability.
- Cost and reimbursement variability: Not all health systems include liquid biopsy in routine cancer care due to cost constraints or policy limitations.
Ongoing clinical trials continue to assess the diagnostic accuracy and cost-effectiveness of liquid biopsy tests. Researchers are developing methods to improve assay sensitivity, differentiate benign from malignant variants, and integrate testing with other clinical data.
Future Direction of Liquid Biopsies in Oncology
As liquid biopsy technology evolves, its use will likely expand across multiple cancer care settings. Some areas of advancement include:
- Improved detection methods: Higher-depth sequencing and digital PCR techniques can enhance the detection of low-abundance ctDNA and rare mutations.
- Personalized treatment adaptation: Liquid biopsies may assist in tailoring therapy based on newly acquired mutations during disease progression.
- Integration with artificial intelligence (AI): Machine learning models can help interpret complex genomic data and stratify risk.
- Combination with radiologic or clinical data: Hybrid approaches may strengthen diagnostic confidence and guide therapeutic decisions.
Researchers must validate these methods through peer-reviewed studies, and physicians must apply them cautiously to ensure correct use in clinical settings.
Takeaway
Liquid biopsies are a noninvasive practice for detecting, monitoring, and understanding cancer at a molecular level. This technology enables safer, faster, and repeatable testing in comparison to traditional biopsies. While not yet a universal replacement for tissue-based diagnostics, liquid biopsies are a valuable tool in several cancers and continue to expand in clinical relevance.
Current applications include identifying actionable mutations, assessing treatment efficacy, and detecting recurrence or residual disease. However, test sensitivity in early-stage cancers, lack of uniform protocols, and reimbursement challenges require further study and resolution. Physicians and patients must evaluate the role of liquid biopsy in individual cases, considering clinical history, disease characteristics, and treatment goals.
As this field progresses, liquid biopsies may further support data-driven care and timely clinical intervention in oncology.
If Cancer Has Been Diagnosed or Returns, Contact New Hope Unlimited
If you or a loved one has received a cancer diagnosis or has concerns about recurrence, contact New Hope Unlimited to learn more about available treatment options. Our team of precision oncology professionals designs treatment plans based on thorough diagnostic evaluations and each patient’s specific condition. We address cancer’s underlying causes, not just the symptoms.
New Hope Unlimited works with patients who seek individualized cancer care that considers the whole person. If you have questions about what to do after a cancer diagnosis or recurrence, our team is available to offer assistance. To speak with a cancer care coordinator, reach out through our website or call us at 480-666-1403.
